Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .
Open-Label Study of Duloxetine for the Treatment of Obsessive-Compulsive Disorder
Background : This study sought to investigate the efficacy of duloxetine for the treatment of obsessive-compulsive disorder ( DSM-IV ) . Methods : Twenty individuals were enrolled in a 17-week , open-label trial of duloxetine at Massachusetts General Hospital . Data were collected between March 2007 and September 2012 . Study measures assessing obsessive-compulsive disorder symptoms , quality of life , depression , and anxiety were administered at baseline and weeks 1 , 5 , 9 , 13 , and 17 . The primary outcome measures were the Yale-Brown Obsessive Compulsive Scale and Clinical Global Improvement scale . Results : For the 12 study completers , pre- and posttreatment analyses revealed significant improvements ( P<.05 ) on clinician- and self-rated measures of obsessive-compulsive disorder symptoms and quality of life . Among the 12 completers , more than one-half ( n=7 ) satisfied full medication response criteria . Intention-to-treat analyses ( n=20 ) showed similar improvements ( P<.05 ) on primary and secondary study outcome measures . Conclusion : The results of this study suggest that duloxetine may provide a significant reduction in symptoms for patients with obsessive-compulsive disorder . Clinical Trials.gov NCT00464698 ; http:// clinical trials.gov/ct2/show/NCT00464698?term=NCT00464698&rank=1
Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .